Repository logo
 

Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome.

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

Van Neste, Christophe  ORCID logo  https://orcid.org/0000-0002-5958-5731
Laird, Alexander 
O'Mahony, Fiach 
Van Criekinge, Wim 
Deforce, Dieter 

Abstract

PURPOSE: Currently, it is unclear to what extent sampling procedures affect the epigenome. Here, this phenomenon was evaluated by studying the impact of artery ligation on DNA methylation in clear cell renal cancer. METHODS: DNA methylation profiles between vascularised tumour biopsy samples and devascularised nephrectomy samples from two individuals were compared. The relevance of significantly altered methylation profiles was validated in an independent clinical trial cohort. RESULTS: We found that six genes were differentially methylated in the test samples, of which four were linked to ischaemia or hypoxia (REXO1L1, TLR4, hsa-mir-1299, ANKRD2). Three of these genes were also found to be significantly differentially methylated in the validation cohort, indicating that the observed effects are genuine. CONCLUSION: Tissue ischaemia during normal surgical removal of tumour can cause epigenetic changes. Based on these results, we conclude that the impact of sampling procedures in clinical epigenetic studies should be considered and discussed, particularly after inducing hypoxia/ischaemia, which occurs in most oncological surgery procedures through which tissues are collected for translational research.

Description

Keywords

Cancer epigenetics, DNA methylation, Hypoxia, Sampling effects, Carcinoma, Renal Cell, DNA Methylation, Epigenomics, Humans, Ischemia, Kidney Neoplasms, Ligation, Nephrectomy, Renal Artery, Transcriptome, Translational Research, Biomedical

Journal Title

Cell Oncol (Dordr)

Conference Name

Journal ISSN

2211-3428
2211-3436

Volume Title

40

Publisher

Springer Science and Business Media LLC
Sponsorship
This work was supported by the Chief Scientist Office, Scotland (ETM37; GDS, DJH), Cancer Research UK (Experimental Cancer Medicine Centre; TP, London, DJH, Edinburgh), Medical Research Council (AL, DJH), Royal College of Surgeons of Edinburgh Robertson Trust (AL), Melville Trust AL), Renal Cancer Research Fund (GDS), Kidney Cancer Scotland (GDS) and an educational grant from Pfizer (TP). CVN and TDM were funded by Ghent University Multidisciplinary Research Partnership 'Bioinformatics: from nucleotides to networks'.